Posts by Tomas G. Neilan, MD, MPH
T1 Value on Cardiac MRI Diagnoses Myocarditis Associated with Checkpoint Inhibitors
Almost all patients with checkpoint inhibitor–associated myocarditis meet modified Lake Louise criteria for nonischemic myocardial injury on cardiac magnetic resonance. The T1 value also has a robust prognostic value.
Immune Checkpoint Inhibitor Therapy Increases Risk of Atherosclerotic Cardiovascular Events
Massachusetts General Hospital researchers have found that patients treated with immune checkpoint inhibitors have higher rates of atherosclerotic cardiovascular events than other cancer patients, but the risk may be modifiable.
Myocarditis from Immune Checkpoint Inhibitors Potentially Mitigated by Early Corticosteroid
In cancer patients with myocarditis associated with immune checkpoint inhibitor therapy, a higher initial dose of corticosteroid and earlier initiation were associated with improved cardiac outcomes.
Cardiac Injury and Cardiovascular Events Are Common After CAR T Therapy
Mass General researchers have reported the first registry data on cardiac toxicities and cardiovascular events among adult patients who received chimeric antigen receptor T-cell therapy.
Hypertension and CVD Are Among Risk Factors for Severe COVID-19
Many patients in a cardiology practice are at risk of developing severe COVID-19 if they become infected with SARS-CoV-2, the new coronavirus.
Cardiology Care During the COVID-19 Pandemic: Guidance for Treating Both Uninfected and Infected Patients
Routine use of ACE inhibitors and angiotensin II receptor blockers should be continued, but these drugs should not be started for patients who develop COVID-19.
Preventing and Detecting Heart Injury in Cancer Patients
In this video, Tomas Neilan, MD, discusses the importance of detecting and preventing heart injury in cancer patients who receive chemotherapy.
Patients with Comorbid Heart Failure, HIV Infection Need Optimal HIV Therapy
Cardiologists at Massachusetts General Hospital have determined that patients hospitalized for heart failure have significantly worse outcomes if they have comorbid HIV, but only if the infection is poorly controlled.
Flu Vaccination May Protect Against Myocarditis Related to Checkpoint Inhibitors
In a retrospective study, researchers at Massachusetts General Hospital have found evidence of a lower risk of myocarditis among cancer patients receiving immune checkpoint inhibitor therapy who have been vaccinated against influenza.
Review: Advanced Imaging May Detect Earlier Signs of Cancer-related Cardiotoxicity
Massachusetts General experts in cardio-oncology and cardiac imaging recently reviewed the application of various modalities—both currently available and emerging—in detecting cardiotoxicity related to cancer treatment.
Researchers Work to Reduce Heart Failure and Stroke After Radiation Therapy
The benefit of radiation and chemotherapy in treating cancer comes at the price of cardiovascular problems. Tomas G. Neilan, MD, and his team are identifying risk factors for heart problems and developing protocols to protect patients' hearts.
Protease inhibitors may increase risk of cardiovascular death in people with HIV and heart failure
A recent study led by Mass General researchers is the first to find that ritonavir-boosted protease inhibitor regimens increase the risk for heart failure events in persons with HIV.
Routine Test May help Find ICI-Related Myocarditis Early
Myocarditis related to immune checkpoint inhibitors may be identified early through EKG and Troponin tests and treated with high dose steroids
Cardioprotection for Cancer Patients and Survivors
Primary or secondary prevention of cardiotoxicity among patients getting treated for cancer, a call for protective measures.
Dr. Neilan received his M.D. from University College Dublin and MPH from Harvard School of Public Health. He completed internal medicine residency and cardiology training at the Mater Misericordiae Hospital in Dublin and again at Massachusetts General Hospital. He has also completed extensive training in echocardiography at Massachusetts General Hospital and cardiac magnetic resonance at the Brigham and Women's Hospital. Dr. Neilan is an Assistant Professor of Medicine at Harvard Medical School, the Director of the Cardio-Oncology Program and the Co-Director of the Cardiac MR PET CT Program.
Dr. Neilan has had a long-standing clinical and research interest in the cardiovascular care of patients with cancer. Cardiovascular disease is a leading cause of death and disability among cancer survivors and cardiovascular care for patients with cancer requires a tailored approach that is unique for each patient. He is specifically interested in how we can improve on the methods for detection of the cardiac toxicity after chemotherapy and radiotherapy and to use that information to determine how we care for patients.